Multi-mechanistic oncolytic poxvirus JX-594 provides survival benefit for liver cancer patients

被引：0
|
作者：
Riedmann, Eva M.
机构：
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2012年 / 8卷 / 01期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：2 / 2
页数：1
相关论文
共 50 条
  • [1] Clinical proof-of-concept with JX-594, a novel targeted multi-mechanistic oncolytic poxvirus, in patients with refractory liver tumors
    Liu, T.
    Park, B.
    Hwang, T.
    Kwon, H.
    Oh, S.
    Han, S.
    Moon, A.
    Speth, K.
    Pinedo, H. M.
    Bell, J.
    Kirn, D. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Clinical proof-of-concept with JX-594, a novel targeted multi-mechanistic oncolytic poxvirus, in patients with refractory liver tumors
    Liu, Ta-Chiang
    HUMAN GENE THERAPY, 2008, 19 (10) : 1064 - 1064
  • [3] A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma
    Hwang, Tae-Ho
    Moon, Anne
    Burke, James
    Ribas, Antoni
    Stephenson, Joe
    Breitbach, Caroline J.
    Daneshmand, Manijeh
    De Silva, Naomi
    Parato, Kelley
    Diallo, Jean-Simon
    Lee, Yeon-Sook
    Liu, Ta-Chiang
    Bell, John C.
    Kirn, David H.
    MOLECULAR THERAPY, 2011, 19 (10) : 1913 - 1922
  • [4] JX-594, a targeted oncolytic poxvirus for the treatment of cancer
    Merrick, Alison E.
    Ilett, Elizabeth J.
    Melcher, Alan A.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (12) : 1372 - 1382
  • [5] JX-594, A TARGETED MULTI-MECHANISTIC ONCOLYTIC POXVIRUS, IS WELL-TOLERATED AND EXHIBITS ANTI-TUMOR ACTIVITY IN PATIENTS WITH PRIMARY LIVER CANCER AND LIVER METASTASES
    Heo, J.
    Cho, M.
    Reid, T.
    Lim, H. Y.
    Ruo, L.
    Kim, C. W.
    Bloomston, M.
    Rhee, B. -G.
    Oh, S. Y.
    Park, B. -H.
    Chung, H. C.
    Patt, R.
    Breitbach, C.
    Hwang, T. -H.
    Bell, J. C.
    Kirn, D. H.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S58 - S58
  • [6] JX-594, a targeted multi-mechanistic oncolytic poxvirus, infects tumor vasculature and causes acute tumor vascular disruption and necrosis in advanced cancer patients
    Breitbach, C.
    Patt, R.
    De Silva, N.
    Parato, K.
    Daneshmand, M.
    Hickman, T.
    Bell, J. C.
    Kirn, D. H.
    EJC SUPPLEMENTS, 2010, 8 (07): : 128 - 128
  • [7] JX-594, a targeted multi-mechanistic oncolytic poxvirus, selectively infects tumor vasculature and causes acute tumor vascular disruption and necrosis in advanced cancer patients
    Breitbach, Caroline
    Arulanandam, Rozanne
    Patt, Richard
    De Silva, Naomi
    Parato, Kelley
    Daneshmand, Manijeh
    Hickman, Theresa
    Bell, John C.
    Kim, David H.
    CANCER RESEARCH, 2011, 71
  • [8] Intravenous Phase I Clinical Proof-of-Concept Trial with JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, in Patients with Refractory Metastatic Cancers
    Burke, James
    Stephenson, Joe
    Pelusio, Adina
    Liu, Ta-Chiang
    Breitbach, Caroline
    Hwang, Taeho
    Moon, Anne
    Parato, Kelley
    Daneshmand, Manijeh
    Bell, John C.
    Kirn, David H.
    MOLECULAR THERAPY, 2009, 17 : S218 - S218
  • [9] A RANDOMIZED, CONTROLLED PHASE 2 CLINICAL TRIAL OF JX-594, A TARGETED MULTI-MECHANISTIC ONCOLYTIC POXVIRUS, IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: FINAL DATA
    Heo, Jeong
    Reid, Tony
    Ruo, Leyo
    Bloomston, Mark
    Lim, Ho Yeong
    Chung, Hyn Cheol
    Kim, Chang Won
    Rose, Steven C.
    Rhee, Byung-Geon
    Patt, Richard H.
    Lencioni, Riccardo
    Hickman, Theresa
    Breitbach, Caroline
    Moon, Anne
    Burke, James
    Bell, John C.
    Hwang, Tae-Ho
    Kirn, David
    HEPATOLOGY, 2011, 54 : 1426A - 1426A
  • [10] Demonstration of Safety and Antitumoral Activity of JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, Following Intravenous Infusion and/or Intratumoral Injections in Patients with Refractory Metastatic Cancers
    Breitbach, C. J.
    Burke, J.
    Moon, A.
    Hwang, T. H.
    Bell, J. C.
    Kirn, D. H.
    HUMAN GENE THERAPY, 2011, 22 (10) : A12 - A12
12345